vs
Side-by-side financial comparison of IonQ, Inc. (IONQ) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $61.9M, roughly 1.7× IonQ, Inc.). IonQ, Inc. runs the higher net margin — 1217.8% vs -29.4%, a 1247.2% gap on every dollar of revenue. On growth, IonQ, Inc. posted the faster year-over-year revenue change (428.5% vs 16.9%). Twist Bioscience Corp produced more free cash flow last quarter ($-34.8M vs $-83.3M).
IonQ, Inc. is an American quantum computing hardware and software company headquartered in College Park, Maryland. The company develops general-purpose trapped ion quantum computers and accompanying software to generate, optimize, and execute quantum circuits.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
IONQ vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $61.9M | $103.7M |
| Net Profit | $753.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | -369.4% | -31.7% |
| Net Margin | 1217.8% | -29.4% |
| Revenue YoY | 428.5% | 16.9% |
| Net Profit YoY | 473.1% | 3.4% |
| EPS (diluted) | $2.60 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $61.9M | $103.7M | ||
| Q3 25 | $39.9M | — | ||
| Q2 25 | $20.7M | — | ||
| Q4 24 | $11.7M | — | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | $11.4M | — |
| Q4 25 | $753.7M | $-30.5M | ||
| Q3 25 | $-1.1B | — | ||
| Q2 25 | $-176.8M | — | ||
| Q4 24 | $-202.0M | — | ||
| Q3 24 | $-52.5M | — | ||
| Q2 24 | $-37.6M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q4 25 | -369.4% | -31.7% | ||
| Q3 25 | -423.5% | — | ||
| Q2 25 | -776.0% | — | ||
| Q4 24 | -661.9% | — | ||
| Q3 24 | -428.5% | — | ||
| Q2 24 | -430.0% | — |
| Q4 25 | 1217.8% | -29.4% | ||
| Q3 25 | -2646.3% | — | ||
| Q2 25 | -854.5% | — | ||
| Q4 24 | -1725.0% | — | ||
| Q3 24 | -423.4% | — | ||
| Q2 24 | -330.0% | — |
| Q4 25 | $2.60 | $-0.50 | ||
| Q3 25 | $-3.58 | — | ||
| Q2 25 | $-0.70 | — | ||
| Q4 24 | $-0.95 | — | ||
| Q3 24 | $-0.24 | — | ||
| Q2 24 | $-0.18 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.8B | $456.1M |
| Total Assets | $6.6B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $197.9M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $546.9M | — | ||
| Q4 24 | $340.3M | — | ||
| Q3 24 | $365.7M | — | ||
| Q2 24 | $369.8M | — |
| Q4 25 | $3.8B | $456.1M | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q4 24 | $383.9M | — | ||
| Q3 24 | $435.7M | — | ||
| Q2 24 | $463.3M | — |
| Q4 25 | $6.6B | $638.1M | ||
| Q3 25 | $4.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q4 24 | $508.4M | — | ||
| Q3 24 | $497.9M | — | ||
| Q2 24 | $517.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-74.5M | $-24.8M |
| Free Cash FlowOCF − Capex | $-83.3M | $-34.8M |
| FCF MarginFCF / Revenue | -134.6% | -33.5% |
| Capex IntensityCapex / Revenue | 14.2% | 9.6% |
| Cash ConversionOCF / Net Profit | -0.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-307.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-74.5M | $-24.8M | ||
| Q3 25 | $-123.1M | — | ||
| Q2 25 | $-52.6M | — | ||
| Q4 24 | $-39.4M | — | ||
| Q3 24 | $-19.2M | — | ||
| Q2 24 | $-26.6M | — |
| Q4 25 | $-83.3M | $-34.8M | ||
| Q3 25 | $-127.2M | — | ||
| Q2 25 | $-53.8M | — | ||
| Q4 24 | $-43.0M | — | ||
| Q3 24 | $-23.0M | — | ||
| Q2 24 | $-34.1M | — |
| Q4 25 | -134.6% | -33.5% | ||
| Q3 25 | -319.1% | — | ||
| Q2 25 | -259.8% | — | ||
| Q4 24 | -367.4% | — | ||
| Q3 24 | -185.3% | — | ||
| Q2 24 | -299.3% | — |
| Q4 25 | 14.2% | 9.6% | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | 5.8% | — | ||
| Q4 24 | 30.7% | — | ||
| Q3 24 | 30.4% | — | ||
| Q2 24 | 65.8% | — |
| Q4 25 | -0.10× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IONQ
| Other | $31.2M | 50% |
| Platform Consulting And Support Services | $30.7M | 50% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
